TY - JOUR
T1 - Drug-Induced Dyskinesia, Part 2
T2 - Treatment of Tardive Dyskinesia
AU - Vijayakumar, Dhanya
AU - Jankovic, Joseph
N1 - Publisher Copyright:
© 2016 Springer International Publishing Switzerland.
PY - 2016/5/1
Y1 - 2016/5/1
N2 - Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. The main types of drug-induced dyskinesias include levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and tardive syndrome (TS), typically present in patients with psychiatric or gastrointenstinal disorders treated with dopamine receptor blocking drugs, also referred to as neuroleptics. Besides preventive measures (i.e., avoiding the use of the offending drugs), general treatment strategies include slow taper of the offending agent and use of dopamine-depleting agents like tetrabenazine. Botulinum toxin may be helpful for wearing off focal dystonia and some forms of tardive dystonia. Deep brain stimulation is usually reserved for patients with disabling motor fluctuations, LID, and for severe TS that cannot be managed medically.
AB - Dyskinesias encompass a variety of different hyperkinetic phenomenologies, particularly chorea, dystonia, stereotypies, and akathisia. The main types of drug-induced dyskinesias include levodopa-induced dyskinesia (LID) in patients with Parkinson's disease and tardive syndrome (TS), typically present in patients with psychiatric or gastrointenstinal disorders treated with dopamine receptor blocking drugs, also referred to as neuroleptics. Besides preventive measures (i.e., avoiding the use of the offending drugs), general treatment strategies include slow taper of the offending agent and use of dopamine-depleting agents like tetrabenazine. Botulinum toxin may be helpful for wearing off focal dystonia and some forms of tardive dystonia. Deep brain stimulation is usually reserved for patients with disabling motor fluctuations, LID, and for severe TS that cannot be managed medically.
UR - http://www.scopus.com/inward/record.url?scp=84964330700&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84964330700&partnerID=8YFLogxK
U2 - 10.1007/s40265-016-0568-1
DO - 10.1007/s40265-016-0568-1
M3 - Review article
C2 - 27091214
AN - SCOPUS:84964330700
SN - 0012-6667
VL - 76
SP - 779
EP - 787
JO - Drugs
JF - Drugs
IS - 7
ER -